A topical 1% copper tripeptide (Glycyl-L-Histidyl-L-Lysine copper) serum, dispatched from within the EU and supplied strictly for laboratory research. Every batch is independently HPLC-tested, with the certificate of analysis published before dispatch.
No spam. One email when stock is confirmed.
Baltic Peptides was built on a simple idea: research materials should come with proof, not promises. We keep a focused catalogue of well-characterised compounds, test every batch independently, and publish the paperwork before a single order ships — so researchers can trust what's in the vial without taking our word for it.
The GHK-Cu serum is part of our copper peptide programme, sitting alongside the lyophilised GHK-Cu vial for teams comparing topical and injectable delivery routes.
A batch-specific certificate of analysis is published before dispatch, and the lot you receive matches that document.
Purity is verified by reverse-phase HPLC at an accredited European laboratory, independent of our own team.
Everything ships from within the EU with lot-level tracking, so any batch can be traced back to its test data.
GHK-Cu (Glycyl-L-Histidyl-L-Lysine bound to copper) is a naturally occurring copper-binding tripeptide first identified in human plasma in the 1970s. It has one of the most extensively documented research profiles in cutaneous biology. This serum delivers the compound in a topical 1% format — distinct from a lyophilised injectable vial — suited to cutaneous and transdermal delivery research, in-vitro skin-model work, and comparative delivery-format studies.
Studied for its relationship to fibroblast activity and type I / type III collagen production, alongside collagen-degrading matrix metalloproteinases.
The copper component is linked in research literature to superoxide dismutase activity and gene expression associated with oxidative-stress defence.
A topical format allows researchers to model skin-barrier function and keratinocyte behaviour under cutaneous exposure, distinct from an injectable route.
Introduces a research axis of its own — bioavailability via the transdermal route versus injectable, an active area of skin-biology investigation.
| Compound | GHK-Cu (Glycyl-L-Histidyl-L-Lysine Copper) · copper tripeptide complex |
| Active concentration | 1% GHK-Cu topical serum |
| GHK-Cu purity | ≥99% (HPLC verified per batch) |
| CAS number | 49557-75-7 |
| Format | Topical serum · clear to pale blue gel-liquid |
| Volume | 30ml |
| Storage — unopened | Cool, dark place · room temperature acceptable |
| Storage — opened | Refrigerate · 2–8°C · use within 3 months |
| Certificate of analysis | Published per batch — accredited HPLC laboratory |
| Research classification | Research Use Only (RUO) |
Supplied ready to use — no reconstitution required. These are standard laboratory handling notes for the material and not instructions for use in humans.
Store in a cool, dark place. Room temperature is acceptable for the sealed product prior to first use.
Refrigerate and use within 3 months of opening. Keep away from direct light and heat.
We'll send one email as soon as the next tested, COA-published batch of GHK-Cu Serum is ready to ship.
No. It is sold strictly for laboratory research and is not a medicine, supplement, or food. Ordering confirms you are a qualified researcher.
Every batch is HPLC-tested, with the exact figure shown on its certificate of analysis. Specification is ≥99% GHK-Cu, and the published COA matches the lot received.
The vial delivers GHK-Cu as a lyophilised powder requiring reconstitution, intended for systemic or injectable research protocols. This serum is a pre-formulated topical 1% solution for transdermal delivery-route research — same compound, distinct format and research application.
Yes — every order dispatches from within the EU for fast, customs-free delivery, with full tracked delivery and lot traceability.
Yes. The COA for the batch received is published and traceable by lot number, covering purity (≥99% HPLC), test method, and batch identifier.